Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 12 of 12 results for cannabis-based medicinal products

  1. Cannabis-based medicinal products (NG144)

    This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

    NICE guideline
    Last updated
    22 March 2021
    View recommendations

    Sections for NG144

  2. What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with chemotherapy-induced nausea and vomiting which persists with optimised conventional antiemetics?

    Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with...

    Research recommendation
    Published
    10 February 2020

  3. For children and young people with intractable cancer-related pain and pain associated with specific diseases (such as epidermolysis bullosa), what is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on to standard treatment to improve symptoms compared with treatment with standard care?

    epidermolysis bullosa), what is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on to standard...

    Research recommendation
    Published
    10 February 2020

  4. What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment in babies, children and young people with chemotherapy-induced nausea or vomiting which persists with optimised conventional antiemetics?

    Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment in babies, children and...

    Research recommendation
    Published
    10 February 2020

  5. What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with persistent nausea or vomiting not caused by chemotherapy which hasn't fully responded to optimised conventional antiemetics?

    Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with...

    Research recommendation
    Published
    10 February 2020

  6. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NG193)

    This guideline covers assessing all chronic pain (chronic primary pain, chronic secondary pain, or both) and managing chronic primary pain in people aged 16 years and over. Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease.

    NICE guideline
    Published
    7 April 2021
    View recommendations

    Sections for NG193

  7. What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for babies, children and young people with persistent nausea or vomiting not caused by chemotherapy which hasn't fully responded to optimised conventional antiemetics?

    Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for babies, children...

    Research recommendation
    Published
    10 February 2020

  8. What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young people and adults with spasticity? In particular, what is the impact of spasticity on improvements in quality of life?

    Question What is the clinical and cost effectiveness of cannabis-based medicinal products other than THC: CBD spray for children, young...

    Research recommendation
    Published
    10 February 2020

  9. What is the clinical and cost effectiveness of CBD in epileptic disorders in children, young people and adults?

    Why the committee made the research recommendationsThe only cannabis-based medicinal product...

    Research recommendation
    Published
    10 February 2020

  10. Does the addition of THC to CBD have an effect on seizure frequency, brain structure and neuropsychological performance when compared with both CBD alone and placebo in epileptic disorders in children, young people and adults?

    Why the committee made the research recommendationsThe only cannabis-based medicinal product...

    Research recommendation
    Published
    10 February 2020

  11. For adults with fibromyalgia or persistent treatment-resistant neuropathic pain, what is the clinical and cost effectiveness of cannabidiol (CBD), containing no, or traces of, delta-9-tetrahydrocannabinol (THC), as an add-on to standard treatment?

    evidence did not show a reduction in opioid use in people prescribed medicinal cannabis. Because the number of people who...

    Research recommendation
    Published
    10 February 2020

  12. Multiple sclerosis in adults: management (NG220)

    This guideline covers diagnosing and managing multiple sclerosis in people aged 18 and over. It aims to improve the quality of life for people with multiple sclerosis by promoting prompt and effective symptom management and relapse treatment, and comprehensive reviews.

    NICE guideline
    Published
    22 June 2022
    View recommendations

    Sections for NG220